Verve Therapeutics received the formal FDA letter outlining what the agency wants to see before it lifts the clinical hold placed on the biotech’s gene-editing therapy. The lifting of a clinical hold on another experimental genetic medicine was among the other recent regulatory news from the past week, which included two drug approvals and one rejection.